ReBio Pharma to Present Abstract at 2024 Controlled Release Society (CRS) Annual Meeting
Turku, Finland – ReBio Pharma has announced that it will present an abstract entitled “Optimizing Injectable in situ Forming Implants for Sustained Release of Ophthalmic Therapeutics” at the 2024 Annual Controlled Release Society (CRS) Meeting, to be held July 8-12 in Bologna, Italy.
The abstract will be presented by Valerie Eta, Ph.D., a Finland-based ReBio researcher who focuses on PLGA-based in situ forming implants (ISFI) for drug delivery, and Jukka Tuominen, D.Sc., ReBio’s Chief Technology Officer (CTO), who leads development of bioresorbable polymers for pharmaceutical formulation.
ISFI for sustained release has long attracted interest due to its potential as an efficient long-term delivery platform that can be administered by perio/intraocular injection. This approach can significantly enhance ophthalmic surgical outcomes and disease stability by eliminating medication non-adherence. The abstract will discuss the impact that polymer specifications have on ISFI drug release.
ReBio Pharma is a pre-clinical stage biotechnology company with an injectable bioresorbable sustained release delivery platform for ophthalmic therapeutics. The SiSu® platform is a novel, proprietary formulation technology for the sustained treatment of chronic eye disease that addresses the safety and efficacy challenges of other sustained release injectables.
About ReBio Pharma
ReBio Pharma is a pre-clinical stage biotechnology company that has developed SiSu®, a novel, proprietary formulation technology that solves the safety and efficacy challenges other sustained release approaches have been unable to resolve. SiSu® is designed to steadily release effective levels of therapeutics within the eye while safely dissolving once drug release is completed, and can be tuned to the drug, indication, and duration of release required. ReBio Pharma is leveraging Sisu® to create a new franchise to transform the standard of care in the treatment of vision-threatening chronic eye diseases. Discover more at www.rebiopharma.com.